Can-Fite BioPharma Ltd. CANF 深 滬
已收盤 07-31 16:00:00 美东时间
3.15
-0.130
-3.96%
華盛通- 最 高3.36
- 今 開3.36
- 成交量 1.55万股
- 最 低 3.15
- 昨 收 3.28
- 總市值 674.90万
- 52周最高 14.00
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 2.56
- 委 比 -56.25%
- 總股本 214.25万
- 歷史最高 28380.00
- 量 比 0.51
- 振 幅 6.40%
- 歷史最低 3.15
- 每 手 1
- 風險率 3.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Can-Fite BioPharma announced that the Australian Patent Office has allowed a patent for "Treatment of Advanced Metastatic Cancer," strengthening its intellectual property around Namodenoson. Namodenoson, targeting A3 adenosine receptors, is in pivotal Phase 3 for hepatocellular carcinoma and Phase 2a for pancreatic cancer, showing promising safety and efficacy. The patent reinforces Can-Fite's oncology portfolio and extends protection in a major ...
07-14 11:00
Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and in...
07-06 19:06
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite BioPharma has completed enrollment of 247 patients in its pivotal Phase 3 study for Piclidenoson, a treatment for moderate-to-severe plaque psoriasis. The study has reached the pre-specified interim analysis stage under an FDA- and EMA-agreed protocol. Results are expected in Q4 2026/Q1 2027. Piclidenoson, an oral A3 adenosine receptor agonist, targets inflammatory pathways and has shown a favorable safety profile in over 1,500 subjects....
07-06 11:00
Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case
Can-Fite BioPharma Ltd. (NYSE:CANF), a clinical-stage biotech, saw its shares jump on Friday after the company secured a Japanese patent allowance for its anti-obesity technology. The Japanese Patent Office allowed Patent Application No. 2025-049941, covering the use of A3 adenosine receptor agonist...
06-26 22:08
Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biot...
06-26 19:04
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite BioPharma Ltd. announced that the Japan Patent Office has allowed a patent for Namodenoson, its lead drug candidate, covering its use for fat loss and treating obesity and metabolic disorders. This milestone strengthens Can-Fite's global intellectual property portfolio, which already includes patent protections in major markets like the U.S., Canada, Australia, and Israel. The patent allowance underscores Namodenoson's potential as a dif...
06-26 11:00
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite BioPharma Ltd. will participate in the BIO International Convention 2026 to discuss licensing and commercialization opportunities for its clinical-stage pipeline, including Namodenoson for advanced hepatocellular carcinoma and Piclidenoson for inflammatory diseases. The company's A3AR platform has shown a favorable safety profile in over 1,600 patients and has generated $20 million in licensing agreements. Can-Fite aims to maximize globa...
06-17 11:00
Can-Fite Highlights Pancreatic Cancer Drug Progress
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today highlighted
06-02 19:02
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
ASCO 2026会议上，RAS抑制在胰腺癌治疗中的重要性得到进一步强调。Can-Fite BioPharma Ltd.的Namodenoson通过抑制RAS、Wnt/β-catenin和NF-κB信号通路，展现出显著的抗肿瘤活性。其IIa期临床试验显示，部分患者实现长期疾病控制，包括一名患者持续治疗近16个月。Namodenoson已获FDA孤儿药认定，针对胰腺癌的治疗潜力备受关注。胰腺癌因其高死亡率和有限治疗手段，亟需创新疗法，而Namodenoson的多通路机制和良好安全性为其开发提供了有力支持。
06-02 11:00
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
